Preskoči na vsebino

Onkologija

Anemia Management

Erythropoiesis-Stimulating Agents

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (odpre novo okno)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Vir‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indeksirano‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (odpre novo okno)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (odpre novo okno)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Vir‎: Acta Haematol 2007;117(3):162-7.

Indeksirano‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (odpre novo okno)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (odpre novo okno)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Vir‎: Am J Hematol 2013;88(12):990-6.

Indeksirano‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (odpre novo okno)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (odpre novo okno)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Vir‎: J Clin Oncol 2011;29(28):3791-7.

Indeksirano‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (odpre novo okno)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (odpre novo okno)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Vir‎: Cancer 2012;118(3):848-55.

Indeksirano‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (odpre novo okno)

Management of anemia in cancer patients. (odpre novo okno)

Calabrich A, Katz A.

Vir‎: Future Oncol 2011;7(4):507-17.

Indeksirano‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (odpre novo okno)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (odpre novo okno)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Vir‎: BJU Int 2011;108(10):1582-7.

Indeksirano‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (odpre novo okno)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (odpre novo okno)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Vir‎: J Clin Oncol 2010;28(13):2239-45.

Indeksirano‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (odpre novo okno)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (odpre novo okno)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Vir‎: Br J Cancer 2011;105(9):1267-72.

Indeksirano‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (odpre novo okno)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (odpre novo okno)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Vir‎: J Intern Med 2017;281(3):284-99.

Indeksirano‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (odpre novo okno)

How I treat cancer-associated anemia. (odpre novo okno)

Gilreath JA, Rodgers GM

Vir‎: Blood 2020;136(7):801-13.

Indeksirano‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (odpre novo okno)

Update on safety of ESAs in cancer-induced anemia. (odpre novo okno)

Glaspy J.

Vir‎: J Natl Compr Canc Netw 2012;10(5):659-66.

Indeksirano‎: PubMed 22570294

https://www.ncbi.nlm.nih.gov/pubmed/22570294 (odpre novo okno)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (odpre novo okno)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Vir‎: Eur J Haematol. 2023 110(4):354-61.

Indeksirano‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (odpre novo okno)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (odpre novo okno)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Vir‎: Int J Hematol 2015;102(4):401-12.

Indeksirano‎: PubMed 26323997

DOI‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (odpre novo okno)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (odpre novo okno)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Vir‎: Cancer 2013;119(1):107-14.

Indeksirano‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (odpre novo okno)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (odpre novo okno)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Vir‎: J Natl Cancer Inst 2013;105(14):1018-26.

Indeksirano‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (odpre novo okno)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (odpre novo okno)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Vir‎: Cancer Sci 2013;104(4):481-5.

Indeksirano‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (odpre novo okno)

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (odpre novo okno)

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

Vir‎: Br J Haematol 2019;184(2):134-60.

Indeksirano‎: PubMed 30549002

DOI‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 (odpre novo okno)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (odpre novo okno)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Vir‎: Support Care Cancer 2012;20(1):159-65.

Indeksirano‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (odpre novo okno)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (odpre novo okno)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Vir‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indeksirano‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (odpre novo okno)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (odpre novo okno)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Vir‎: Oncologist 2010;15(9):935-43.

Indeksirano‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (odpre novo okno)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (odpre novo okno)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Vir‎: Lung Cancer 2012;76(3):478-85.

Indeksirano‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (odpre novo okno)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (odpre novo okno)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Vir‎: Eur J Haematol 2016;97(1):33-8.

Indeksirano‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (odpre novo okno)

Intravenous Iron

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (odpre novo okno)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Vir‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indeksirano‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (odpre novo okno)

Intravenous iron in oncology. (odpre novo okno)

Auerbach M, Ballard H.

Vir‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Indeksirano‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (odpre novo okno)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (odpre novo okno)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Vir‎: Int J Colorectal Dis 2016;31(3):543-51.

Indeksirano‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (odpre novo okno)

How I treat cancer-associated anemia. (odpre novo okno)

Gilreath JA, Rodgers GM

Vir‎: Blood 2020;136(7):801-13.

Indeksirano‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (odpre novo okno)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (odpre novo okno)

Gilreath JA, Stenehjem DD, Rodgers GM.

Vir‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Indeksirano‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (odpre novo okno)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (odpre novo okno)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Vir‎: Eur J Haematol. 2023 110(4):354-61.

Indeksirano‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (odpre novo okno)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (odpre novo okno)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Vir‎: Curr Oncol. 2023 24;30(9):7836-51.

Indeksirano‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (odpre novo okno)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (odpre novo okno)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Vir‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Indeksirano‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (odpre novo okno)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (odpre novo okno)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Vir‎: World J Gastroenterol 2014;20(8):1972-85.

Indeksirano‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (odpre novo okno)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (odpre novo okno)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Vir‎: South Asian J Cancer. 2023 15;12(2):93-9.

Indeksirano‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (odpre novo okno)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (odpre novo okno)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Vir‎: J Clin Oncol 2008;26(10):1619-25.

Indeksirano‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (odpre novo okno)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (odpre novo okno)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Vir‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Indeksirano‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (odpre novo okno)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (odpre novo okno)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Vir‎: Ann Oncol 2013;24(2):475-82.

Indeksirano‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (odpre novo okno)

Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions. (odpre novo okno)

Van Doren L, Steinheiser M, Boykin K, Taylor KJ, Menendez M, Auerbach M

Vir‎: Am J Hematol 2024;99(7):1338-48.

Indeksirano‎: PubMed 38282557

DOI‎: 10.1002/ajh.27220

https://pubmed.ncbi.nlm.nih.gov/38282557/ (odpre novo okno)

ONKOLOGIJA
Anemia Management
slovenščina
Anemia Management
https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Odbori za stike z bolnišnicami (OSB)

Kontaktirajte z lokalnim predstavnikom, ki je brezplačno na voljo zdravnikom, ki zdravijo Jehovove priče.

Kontakt

Paketi informacij za zdravnike

Teme so med drugim: klinični pristopi za preprečevanje in obvladovanje krvavitve in anemije brez transfuzije krvi; verski in etični pogled Jehovovih prič na zdravljenje; storitve, ki jih Jehovove priče nudijo zdravstvenemu osebju po svoji svetovni mreži odborov za stike z bolnišnicami.

Ogled gradiva

Videoposnetki

Zdravnikom, ki zdravijo Jehovove priče, so predstavljene možnosti zdravljenja ter medicinski in etični vidiki.

Ogled videoposnetkov